{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:24:13Z","timestamp":1788387853167,"version":"build-2803163510"},"reference-count":63,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Diagnostic Pathology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.semdp.2025.150976","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T16:43:09Z","timestamp":1764261789000},"page":"150976","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Secondary neoplasms following treatment for multiple myeloma"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9275-6056","authenticated-orcid":false,"given":"Sharon Koorse","family":"Germans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Weinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.semdp.2025.150976_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100397","article-title":"Fifth edition of the World Health Classification of Tumors of the Hematopoietic and lymphoid Tissue: myeloid neoplasms","volume":"37","author":"Loghavi","year":"2024","journal-title":"Mod Pathol"},{"issue":"11","key":"10.1016\/j.semdp.2025.150976_bib0002","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.semdp.2025.150976_bib0003","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1056\/NEJM197011192832101","article-title":"Multiple myeloma and acute myelomonocytic leukemia","volume":"283","author":"Kyle","year":"1970","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.semdp.2025.150976_bib0004","first-page":"4507","article-title":"Increased incidence of a second lymphoproliferative malignancy in patients with multiple myeloma\u2014A SEER based study","volume":"32","author":"Chakraborty","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/j.semdp.2025.150976_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100757","article-title":"Second primary malignancies in multiple myeloma: a review","volume":"46","author":"Poh","year":"2021","journal-title":"Blood Rev"},{"key":"10.1016\/j.semdp.2025.150976_bib0006","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s12185-018-2538-8","article-title":"Risk of secondary primary malignancies in multiple myeloma patients with or without autologous stem cell transplantation","volume":"109","author":"Yamasaki","year":"2019","journal-title":"Int J Hematol"},{"key":"10.1016\/j.semdp.2025.150976_bib0007","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.leukres.2018.07.016","article-title":"Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma","volume":"74","author":"Radivoyevitch","year":"2018","journal-title":"Leuk Res"},{"key":"10.1016\/j.semdp.2025.150976_bib0008","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.bbmt.2014.12.028","article-title":"New cancers after autotransplantations for multiple myeloma","volume":"21","author":"Mahindra","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.semdp.2025.150976_bib0009","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1038\/bcj.2014.63","article-title":"Variable risk of second primary malignancy in multiple myeloma patients of different ethnic subgroups","volume":"4","author":"Ailawadhi","year":"2014","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.semdp.2025.150976_bib0010","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.3109\/10428194.2015.1132419","article-title":"Connect MM\u00ae \u2013 the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide","volume":"57","author":"Rifkin","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.semdp.2025.150976_bib0011","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.clml.2014.07.001","article-title":"Characteristics and outcomes of patients with multiple myeloma who develop therapy\u2011related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia","volume":"15","author":"Pemmaraju","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.semdp.2025.150976_bib0012","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem\u2011cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semdp.2025.150976_bib0013","first-page":"e518","article-title":"Second primary malignancies in multiple myeloma: an overview and IMWG consensus","volume":"7","author":"Musto","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.semdp.2025.150976_bib0014","first-page":"267","article-title":"Secondary primary malignancies in lenalidomide maintenance therapy: meta-analysis of phase III trials","volume":"59","author":"Foran","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.semdp.2025.150976_bib0015","first-page":"2123","article-title":"Prognostic significance of high\u2011risk cytogenetic abnormalities in multiple myeloma","volume":"26","author":"Usmani","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.semdp.2025.150976_bib0016","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1182\/blood-2018-09-825331","article-title":"Toward personalized treatment in multiple myeloma based on molecular characteristics","volume":"133","author":"Pawlyn","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.semdp.2025.150976_bib0017","first-page":"689","article-title":"Prognostic and predictive performance of the Revised International Staging System in newly diagnosed multiple myeloma patients","volume":"126","author":"Kuiper","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.semdp.2025.150976_bib0018","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem\u2011cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.semdp.2025.150976_bib0019","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1016\/S2352-3026(17)30140-0","article-title":"Updated analysis of CALGB 100104 assessing lenalidomide versus placebo maintenance after single autologous stem\u2011cell transplantation for multiple myeloma: a randomized, double\u2011blind, phase 3 trial","volume":"4","author":"Holstein","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.semdp.2025.150976_bib0020","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/14737140.2019.1674142","article-title":"The evolving role of maintenance therapy following autologous stem cell transplantation in multiple myeloma","volume":"19","author":"Merz","year":"2019","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.semdp.2025.150976_bib0021","first-page":"1497","article-title":"Therapy-related myeloid neoplasms in multiple myeloma: epidemiology and outcomes","volume":"62","author":"Giri","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"15","key":"10.1016\/j.semdp.2025.150976_bib0022","first-page":"3624","article-title":"Therapy-related myeloid neoplasms after autologous transplantation in multiple myeloma","volume":"4","author":"Olin","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.semdp.2025.150976_bib0023","first-page":"1095","article-title":"Therapy-related acute myeloid leukemia and myelodysplastic syndrome after multiple myeloma","volume":"37","author":"Shah","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.semdp.2025.150976_bib0024","first-page":"2414","article-title":"Therapy-related myelodysplasia and acute myeloid leukemia with balanced chromosome aberrations as a characteristic feature","volume":"16","author":"Andersen","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.semdp.2025.150976_bib0025","first-page":"407","article-title":"Therapy-related myeloid neoplasms: clinical presentation, risk factors, and treatment","volume":"93","author":"Melchardt","year":"2014","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.semdp.2025.150976_bib0026","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.semdp.2025.150976_bib0027","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular minimal residual disease in acute myeloid leukemia","volume":"378","author":"Jongen-Lavrencic","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semdp.2025.150976_bib0028","first-page":"47","article-title":"TP53 mutations predict outcomes in therapy-related myeloid neoplasms","volume":"16","author":"Zeidan","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"7","key":"10.1016\/j.semdp.2025.150976_bib0029","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the WHO Classification of Haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.semdp.2025.150976_bib0030","first-page":"980","article-title":"Outcomes of patients with TP53-mutated therapy-related myeloid neoplasms","volume":"63","author":"Goyal","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.semdp.2025.150976_bib0031","doi-asserted-by":"crossref","first-page":"eaan4673","DOI":"10.1126\/science.aan4673","article-title":"Clonal hematopoiesis in human aging and disease","volume":"366","author":"Jaiswal","year":"2019","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.semdp.2025.150976_bib0032","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1038\/s41467-020-16805-5","article-title":"Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant","volume":"11","author":"Mouhieddine","year":"2020","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.semdp.2025.150976_bib0033","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/s41375-018-0208-8","article-title":"Clonal hematopoiesis in patients with multiple myeloma undergoing autologous stem cell transplantation","volume":"32","author":"Chitre","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.semdp.2025.150976_bib0034","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13045-025-01676-4","article-title":"Second primary malignancies following CAR T\u2011cell therapy in patients with hematologic malignancies","volume":"18","author":"Umyarova","year":"2025","journal-title":"J Hematol Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.semdp.2025.150976_bib0035","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.1182\/blood-2024-210233","article-title":"Prevalence and mutational make-up of secondary hematologic neoplasms in multiple myeloma patients after CAR\u2011T cell therapy","volume":"144","author":"Waldschmidt","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.semdp.2025.150976_bib0036","first-page":"1041","article-title":"Allogeneic transplantation in tMNs: role and outcomes","volume":"7","author":"Weissmann","year":"2023","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.semdp.2025.150976_bib0037","first-page":"2254","article-title":"A phase I\/II study of venetoclax and azacitidine in patients with relapsed\/refractory myelodysplastic syndrome and secondary AML after hypomethylating agent failure","volume":"35","author":"Loke","year":"2021","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.semdp.2025.150976_bib0038","first-page":"784","article-title":"Venetoclax-based therapies for secondary and therapy-related myeloid neoplasms: clinical outcomes and mutation associations","volume":"96","author":"DiNardo","year":"2021","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.semdp.2025.150976_bib0039","first-page":"1371","article-title":"Venetoclax with hypomethylating agents for the treatment of therapy-related myeloid neoplasms","volume":"37","author":"Bhatnagar","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.semdp.2025.150976_bib0040","article-title":"Management of therapy-related myeloid neoplasms in the era of genomic profiling","volume":"56","author":"Abou Dalle","year":"2022","journal-title":"Blood Rev"},{"issue":"3","key":"10.1016\/j.semdp.2025.150976_bib0041","first-page":"28","article-title":"Incidence of lymphomas in MM survivors","volume":"8","author":"Gonsalves","year":"2018","journal-title":"Blood Cancer J"},{"issue":"14","key":"10.1016\/j.semdp.2025.150976_bib0042","first-page":"2123","article-title":"Characteristics and outcomes of therapy-related acute lymphoblastic leukemia in adults: a report from the ECOG\u2011ACRIN Cancer Research Group","volume":"3","author":"Advani","year":"2019","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.semdp.2025.150976_bib0043","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.cpt.2024.06.007","article-title":"Characteristics and outcomes of secondary acute lymphoblastic leukemia (sALL) after multiple myeloma (MM): SEER data analysis in a single-center institution","volume":"3","author":"Jia","year":"2024","journal-title":"Cancer Pathog Ther"},{"issue":"29","key":"10.1016\/j.semdp.2025.150976_bib0044","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.semdp.2025.150976_bib0045","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.semdp.2025.150976_bib0046","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"IFM Investigators. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.semdp.2025.150976_bib0047","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","article-title":"UK NCRI Haemato-oncology Clinical Studies Group. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Jackson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.semdp.2025.150976_bib0048","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/ajcp\/aqaa109","article-title":"Lenalidomide-associated secondary B\u2011lymphoblastic leukemia\/lymphoma\u2014A unique entity: a report of two cases with low\u2011level bone marrow involvement and review of the literature","volume":"154","author":"Germans","year":"2020","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"10.1016\/j.semdp.2025.150976_bib0049","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/hon.2248","article-title":"Lenalidomide and secondary acute lymphoblastic leukemia: a case series","volume":"35","author":"Tan","year":"2017","journal-title":"Hematol Oncol"},{"issue":"12","key":"10.1016\/j.semdp.2025.150976_bib0050","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.3109\/10428194.2013.786072","article-title":"Acute lymphoblastic leukemia developing during maintenance therapy with lenalidomide in a patient with multiple myeloma","volume":"54","author":"Garc\u00eda-Mu\u00f1oz","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"Suppl 2","key":"10.1016\/j.semdp.2025.150976_bib0051","first-page":"S131","article-title":"Three patients with multiple myeloma developing secondary lymphoblastic leukemia: case reports and review of the literature","volume":"102","year":"2016","journal-title":"Tumori"},{"issue":"1","key":"10.1016\/j.semdp.2025.150976_bib0052","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3892\/ol.2016.4728","article-title":"Secondary lymphoblastic leukemia occurring 38 months after the primary diagnosis of multiple myeloma: a case report","volume":"12","author":"Li","year":"2016","journal-title":"Oncol Lett"},{"key":"10.1016\/j.semdp.2025.150976_bib0053","article-title":"Acute lymphoblastic leukemia following lenalidomide maintenance for multiple myeloma: two cases with unexpected presentation and good prognostic features","volume":"2018","author":"Khan","year":"2018","journal-title":"Case Rep Hematol"},{"issue":"6","key":"10.1016\/j.semdp.2025.150976_bib0054","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.12708","article-title":"Dexamethasone and lenalidomide combination therapy for multiple myeloma: immune modulation through cereblon pathways","volume":"164","author":"Gandhi","year":"2014","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.semdp.2025.150976_bib0055","first-page":"e686","article-title":"Therapy-related lymphoproliferative disorders: pathogenesis and diagnostic considerations","volume":"21","author":"Hill","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"10.1016\/j.semdp.2025.150976_bib0056","first-page":"538","article-title":"Management of diffuse large B-cell lymphoma in the elderly","volume":"31","author":"Weinstock","year":"2017","journal-title":"Oncol (Willist Park)"},{"issue":"20","key":"10.1016\/j.semdp.2025.150976_bib0057","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.semdp.2025.150976_bib0058","first-page":"e686","article-title":"Therapy-related lymphoproliferative disorders: pathogenesis and diagnostic considerations","volume":"21","author":"Hill","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"10.1016\/j.semdp.2025.150976_bib0059","first-page":"538","article-title":"Management of diffuse large B-cell lymphoma in the elderly","volume":"31","author":"Weinstock","year":"2017","journal-title":"Oncol (Willist Park)"},{"issue":"7","key":"10.1016\/j.semdp.2025.150976_bib0060","first-page":"538","article-title":"Management of diffuse large B-cell lymphoma in the elderly","volume":"31","author":"Weinstock","year":"2017","journal-title":"Oncol (Willist Park)"},{"issue":"20","key":"10.1016\/j.semdp.2025.150976_bib0061","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.semdp.2025.150976_bib0062","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","article-title":"Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial","volume":"12","author":"Peyrade","year":"2011","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.semdp.2025.150976_bib0063","first-page":"e14","article-title":"R-CHOP versus R-miniCHOP in elderly patients with DLBCL: long-term follow-up of the UK NCRI LY10 trial","volume":"8","author":"Cunningham","year":"2021","journal-title":"Lancet Haematol"}],"container-title":["Seminars in Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740257025001121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740257025001121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T07:49:33Z","timestamp":1768549773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740257025001121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0740257025001121"],"URL":"https:\/\/doi.org\/10.1016\/j.semdp.2025.150976","relation":{},"ISSN":["0740-2570"],"issn-type":[{"value":"0740-2570","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Secondary neoplasms following treatment for multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semdp.2025.150976","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"150976"}}